Literature DB >> 30288810

Updates on the surface antigens of basophils: CD16 on basophils of patients with respiratory or insect venom allergy and the rejection of CD203c and CD63 externalization decoupling by bisindolylmaleimides.

Petr Heneberg1, Kamila Riegerová2, Adéla Říhová2, Daniela Šimčíková1, Petr Kučera2.   

Abstract

BACKGROUND: CD16 was previously suggested to be a new marker of basophils that is subject to downregulation by FcεRI crosslinking. Certain compounds, including supraoptimal concentrations of the PKC inhibitors, bisindolylmaleimides, decouple the release of granules containing CD203c, CD63 and histamine, and may thus help to identify the mechanisms related to the CD16 externalization.
OBJECTIVE: We hypothesized that CD16 is differentially expressed on the surface of basophils in patients with birch pollen or insect venom allergy and is subject to a regulation in response to allergens. We also employed CD203c and CD63 externalization decoupling by bisindolylmaleimides.
METHODS: We performed a basophil activation test coupled with CD16 and histamine detection using cells isolated from patients with allergy to birch pollen or insect venom and negative controls. We employed two PKC inhibitors, bisindolylmaleimide II and Ro 31-8220 at their supraoptimal concentrations and, after difficulties reproducing previously published data, we analyzed the fluorescence of these inhibitors alone. We identified the CD16 isoforms by sequencing nested RT-PCR amplicons from flow cytometry sorted basophils and by cleaving the CD16b GPI anchor using a phospholipase C.
RESULTS: We provide the first evidence that CD16a is expressed as a surface antigen on a small subpopulation of human basophils in patients with respiratory and insect venom allergy, and this antigen shows increased surface expression following allergen challenge or FcεRI crosslinking. We rejected the apparent decoupling of the surface expression of basophil activation markers following the administration of bisindolylmaleimides. CONCLUSIONS & CLINICAL RELEVANCE: The inclusion of αCD16 in negative selection cocktails selects against a subset of basophils that are CD16+ or CD16dim . Using CD16dim basophils and unstained leucocytes, we show that previous studies with supraoptimal concentrations of bisindolylmaleimides are likely flawed and are not associated with the differential expression of CD203c and CD63.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  FcγRIIIA; IgG-mediated anaphylaxis; basophil activation test; bisindolylmaleimide; flow cytometry artifact

Year:  2018        PMID: 30288810     DOI: 10.1111/cea.13288

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  4 in total

1.  Allergen Content of Therapeutic Preparations for Allergen-Specific Immunotherapy of European Paper Wasp Venom Allergy.

Authors:  Johannes Grosch; Antoine Lesur; Stéphanie Kler; François Bernardin; Gunnar Dittmar; Elisabetta Francescato; Simon J Hewings; Constanze A Jakwerth; Ulrich M Zissler; Matthew D Heath; Markus Ollert; Matthias F Kramer; Christiane Hilger; Maria Beatrice Bilò; Carsten B Schmidt-Weber; Simon Blank
Journal:  Toxins (Basel)       Date:  2022-04-15       Impact factor: 5.075

2.  Increased expressions of CD123, CD63, CD203c, and Fc epsilon receptor I on blood leukocytes of allergic asthma.

Authors:  Hua Xie; Liping Chen; Huiyun Zhang; Junling Wang; Yanyan Zang; Mengmeng Zhan; Fangqiu Gu; Shunlan Wang; Shaoheng He
Journal:  Front Mol Biosci       Date:  2022-08-11

3.  Association between Venom Immunotherapy and Changes in Serum Protein-Peptide Patterns.

Authors:  Joanna Matysiak; Eliza Matuszewska; Marek L Kowalski; Sławomir W Kosiński; Ewa Smorawska-Sabanty; Jan Matysiak
Journal:  Vaccines (Basel)       Date:  2021-03-12

4.  Effect of Combined Bee Venom Acupuncture and NSAID Treatment for Non-Specific Chronic Neck Pain: A Randomized, Assessor-Blinded, Pilot Clinical Trial.

Authors:  Boram Lee; Byung-Kwan Seo; O-Jin Kwon; Dae-Jean Jo; Jun-Hwan Lee; Sanghun Lee
Journal:  Toxins (Basel)       Date:  2021-06-23       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.